C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion.

C3.ai Inc (AI) is winning back investors with a management shake-up that could redefine its future after CEO and founder Tom ...

C3.ai (NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...

Investors are hopeful that C3.ai (NYSE: AI) can deliver results similar to Palantir (NASDAQ: PLTR). *Stock prices used were the afternoon prices of July 23, 2025. The video was published on July 25, ...

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of C3.ai's market ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

Jefferies warns of high attrition in TCS following the layoff debacle, while Nasscom posts an impersonal response; Tata Consultancy Services shares continue to tank, falling 25 per cent in six months ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Huntington Ingalls Industries ( NYSE: HII) shares jumped more than 5% in premarket trading Thursday after the U.S. defense ...

The new AI-focused ETF is putting your money where its mouth is, so to speak, by utilizing the very technology it's investing ...